GPR55 contributes to neutrophil recruitment and mechanical pain induction after spinal cord compression in mice

Ono, Teruaki; Yamashita, Tomohiro; Kano, Ryota; Inoue, Mariko; Okada, Shogo; Kano, Koki; Koizumi, Schuichi; Iwabuchi, Kazuhisa; Hirabayashi, Yoshio; Matsuo, Ichiro; Nakashima, Yasuharu; Kamiguchi, Hiroyuki; Kohro, Yuta; Tsuda, Makoto

doi:10.1016/j.bbi.2023.03.008

Cited by 3 publications

(2 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was also shown that the concentration of GPR55 was elevated in the inflamed colon compared to non-inflamed colonic tissues, suggesting their proinflammatory roles [128]. It has been reported that inflammation and neuropathic hypersensitivity were absent following the genetic knockdown of GPR55 in a mouse model of mechanical hyperalgesia using Freund's complete adjuvant [129]. GPR55 was also shown to have crosstalk with CB2 receptors in neutrophil chemotaxis and recruitment [130].…”

Section: Role Of the Expanded Family Of Ecs In Ibdmentioning

confidence: 97%

Pharmacohistory of Cannabis Use—A New Possibility in Future Drug Development for Gastrointestinal Diseases

Thapa,

Warne,

Falasca

2023

IJMS

View full text Add to dashboard Cite

Humans have employed cannabis for multiple uses including medicine, recreation, food, and fibre. The various components such as roots, flowers, seeds, and leaves have been utilized to alleviate pain, inflammation, anxiety, and gastrointestinal disorders like nausea, vomiting, diarrhoea, and inflammatory bowel diseases (IBDs). It has occupied a significant space in ethnomedicines across cultures and religions. Despite multi-dimensional uses, the global prohibition of cannabis by the USA through the introduction of the Marijuana Tax Act in 1937 led to prejudice about the perceived risks of cannabis, overshadowing its medicinal potential. Nevertheless, the discovery of tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis, and the endocannabinoid system renewed scientific interest in understanding the role of cannabis in modulating different conditions, including gastrointestinal disorders. Preparations combining cannabidiol and THC have shown promise in mitigating gut symptoms through anti-inflammatory and motility-enhancing effects. This review revisits the ethnomedicinal use of cannabis in gastrointestinal diseases and emphasizes the need for further research to determine optimal dosages, formulations, and safety profiles of cannabis-based medicines. It also underscores the future potential of cannabinoid-based therapies by leveraging the role of the expanded endocannabinoid system, an endocannabinoidome, in the modulation of gastrointestinal ailments.

show abstract

Section: Role Of the Expanded Family Of Ecs In Ibdmentioning

confidence: 97%

Pharmacohistory of Cannabis Use—A New Possibility in Future Drug Development for Gastrointestinal Diseases

Thapa,

Warne,

Falasca

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…In a recent study in mice, GPR55 signaling contributed to the induction of inflammatory responses and chronic pain via the recruitment of neutrophils, monocytes/macrophages, and T-cells, possibly providing a new target for reducing pain [68]. Another study reported that GPR55-KO mice did not develop mechanical pain in chronic pain models developed by peripheral nerve injury and peripheral tissue inflammation [69].…”

Section: Introductionmentioning

confidence: 99%

Expression of Cannabinoid Receptors in the Trigeminal Ganglion of the Horse

Zamith Cunha,

Semprini,

Salamanca

et al. 2023

IJMS

View full text Add to dashboard Cite

Cannabinoid receptors are expressed in human and animal trigeminal sensory neurons; however, the expression in the equine trigeminal ganglion is unknown. Ten trigeminal ganglia from five horses were collected post-mortem from an abattoir. The expression of cannabinoid receptors type 1 (CB1R) and type 2 (CB2R), and the cannabinoid-related receptors like transient receptor potential vanilloid type 1 (TRPV1), peroxisome proliferator-activated receptor gamma (PPARɣ), and G protein-related receptor 55 (GPR55) in the trigeminal ganglia (TG) of the horse were studied, using immunofluorescence on cryosections and formalin-fixed paraffin-embedded (FFPE) sections. Neurons and glial cells were identified using fluorescent Nissl staining NeuroTrace® and an antibody directed against the glial marker glial fibrillary acidic protein (GFAP), respectively. Macrophages were identified by means of an antibody directed against the macrophages/microglia marker ionized calcium-binding adapter molecule 1 (IBA1). The protein expression of CB1R, CB2R, TRPV1, and PPARɣ was found in the majority of TG neurons in both cryosections and FFPE sections. The expression of GPR55 immunoreactivity was mainly detectable in FFPE sections, with expression in the majority of sensory neurons. Some receptors were also observed in glial cells (CB2R, TRPV1, PPARγ, and GPR55) and inflammatory cells (PPARγ and GPR55). These results support further investigation of such receptors in disorders of equine trigeminal neuronal excitability.

show abstract

Molecular mechanisms and clinical implications of the gold drug auranofin

Shen

Luo

et al. 2023

Coordination Chemistry Reviews

View full text Add to dashboard Cite

GPR55 contributes to neutrophil recruitment and mechanical pain induction after spinal cord compression in mice

Cited by 3 publications

References 55 publications

Pharmacohistory of Cannabis Use—A New Possibility in Future Drug Development for Gastrointestinal Diseases

Pharmacohistory of Cannabis Use—A New Possibility in Future Drug Development for Gastrointestinal Diseases

Expression of Cannabinoid Receptors in the Trigeminal Ganglion of the Horse

Molecular mechanisms and clinical implications of the gold drug auranofin

Contact Info

Product

Resources

About